Market Size & Trends

The cell and gene therapy third-party logistics market was estimated at USD 10.71 billion in 2024 and is projected to grow at a CAGR of 11.05% from 2025 to 2030. The growth of the market is due to advancements in personalized medicines, expansion of clinical trials followed by subsequent approvals, and technological advancements mainly in cold chain logistics. The increasing demand for personalized medicine has transformed healthcare by shifting the focus from generalized treatments to patient-specific therapies. Cell and gene therapies (CGTs) offer customized solutions for previously untreatable conditions. The logistics requirements for CGTs are highly specialized due to their personalized nature, requiring stringent temperature controls, real-time tracking, and rapid delivery.

Technology Landscape

Recent technological advancements have significantly enhanced the efficiency and reliability of 3PL services supporting the cell and gene therapy sector. The integration of real-time cold chain monitoring systems using IoT-enabled devices is one of the most innovative developments in recent years.
Market Concentration & Characteristics

The CGT logistics sector rapidly evolves with AI-driven monitoring solutions that enhance real-time shipment tracking. Blockchain is being integrated to improve supply chain transparency and regulatory compliance.

Large logistics providers are acquiring specialized cold chain firms to expand their CGT capabilities. The industry is witnessing increased consolidation among biopharma-focused logistics companies to strengthen their market presence. Collaborations between tech firms and logistics providers enhance automation and predictive analytics in supply chains. Strategic partnerships are forming to develop end-to-end CGT logistics solutions.
Type Insights
The clinical segment accounted for the highest market share of 83.33% in the cell & gene therapy third-party logistics industry in 2024. The growth of the segment is due to the growing number of cell and gene therapy clinical trials worldwide. For instance, over 1,975 ongoing clinical trials for cell and gene therapy as of Q4 2024. The increasing complexity of early-stage research and stringent regulatory requirements have driven demand for specialized logistics solutions to support trial site distribution, sample collection, and real-time temperature monitoring.

Global Cell And Gene Therapy Third-Party Logistics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the cell and gene therapy third-party logistics market on the basis of type, product, temperature range, therapeutic area, end-use, and region:

Global Cell And Gene Therapy Third-Party Logistics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the cell and gene therapy third-party logistics market on the basis of type, product, temperature range, therapeutic area, end-use, and region:

• Type Outlook (Revenue, USD Million; 2018 - 2030)

  • Clinical

  • Commercial

• Product Outlook (Revenue, USD Million; 2018 - 2030)

  • Cell Therapies

  • Gene Therapies

• Temperature Range Outlook (Revenue, USD Million; 2018 - 2030)

  • Ambient Storage

  • Refrigerated Storage

  • Ultra-Low Temperature Storage

  • Cryogenic Storage

• Therapeutic Area Outlook (Revenue, USD Million; 2018 - 2030)

  • Oncology

  • Neurology

  • Cardiovascular Diseases

  • Ophthalmology

  • Infectious Diseases

  • Others

• End-use Outlook (Revenue, USD Million; 2018 - 2030)

  • Biopharmaceutical Companies

  • CDMOs/CMOs

  • Others